Cargando…
Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies
PURPOSE: Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years. However, long-term safety of OCT has not been documented in placebo-controlled setting. This present analysis pooled safety data from two similarly-designed, randomized,...
Autores principales: | Pivonello, Rosario, Muscogiuri, Giovanna, Holder, Geoffrey, Paul, Michaela, Sarp, Severine, Lesogor, Anastasia, Jordaan, Pierre, Eisinger, Johannes, Colao, Annamaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845597/ https://www.ncbi.nlm.nih.gov/pubmed/29116540 http://dx.doi.org/10.1007/s12020-017-1448-5 |
Ejemplares similares
-
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015) -
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis
por: Strosberg, Jonathan R, et al.
Publicado: (2015) -
Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension
por: Cui, Pei-Jing, et al.
Publicado: (2017) -
Preparation of long-acting microspheres loaded with octreotide for the treatment of portal hypertensive
por: Han, Bing, et al.
Publicado: (2021) -
Influence of Bisphenol A on Type 2 Diabetes Mellitus
por: Provvisiero, Donatella Paola, et al.
Publicado: (2016)